Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgrastim biosimilar - Dong-A ST

Drug Profile

Filgrastim biosimilar - Dong-A ST

Alternative Names: DA 3030; Leucostim; Leukopoeitin - Dong-A ST; Leukostim®; rhG-CSF

Latest Information Update: 16 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
  • Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic neuropathies

Highest Development Phases

  • Marketed Neutropenia
  • Phase II Diabetic neuropathies

Most Recent Events

  • 07 Jan 2020 Clinical development is still ongoing for Neutropenia (Prevention, Chemotherapy-induced) in Indonesia (SC) (NCT03343145)
  • 29 Jul 2019 Dong-A ST completes a phase III trial in Neutropenia (Prevention, Chemotherapy-induced) in Indonesia (SC) (NCT03343145)
  • 05 May 2016 Biocad plans a phase I trial for Leucocytosis (In volunteers) in Russia (SC) (NCT02762799)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top